Zhihuan Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhihuan Zeng has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Tudi Li
Department of Cardiology, The First Affiliated Hospital of Guangdong Pharmaceutical University, China
9 shared publicationsRong Chen
Department of Cardiology, The First Affiliated Hospital of Guangdong Pharmaceutical University, China
6 shared publicationsChunyan Zhu
Department of Cardiology, The First Affiliated Hospital of Guangdong Pharmaceutical University, China
4 shared publicationsZihao Zhou
Guangdong Pharmaceut Univ, Affiliated Hosp 1, Cardiovasc Dept, Guangzhou 510080, Guangdong, Peoples R China
4 shared publications- Junqian Luo
The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510080, Guangdong Province, China
3 shared publications Qing Zhang
Department of Cardiovascular Diseases, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China
3 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1616561
Association between joint physical activity and alcohol intake and all-cause mortality in patients with cardiovascular disease: findings from NHANES 2007–2018
Background: Physical activity and alcohol consumption are both highly prevalent in many countries, while the evidence related to joint effect on physical activity and alcohol consumption on patients with cardiovascular disease (CVD) was still deficient. This study was aimed to investigate the association between joint moderate-to-vigorous physical activity (MVPA) and alcohol intake and all-cause mortality in patients with CVD.Methods: A total of 4,047 participants from the National Health and Nutrition Examination Survey (NHANES) with self-reported CVD history, exercise and alcohol consumption amounts were included this study. Participants were stratified into 12 groups by MVPA level (none/insufficient/sufficient) and alcohol intake (abstainer/light/moderate/heavy). Restricted cubic spline and Cox regression models assessed mortality associations.Results: MVPA showed an L-shaped association with mortality, while alcohol exhibited a U-shaped pattern. The lowest observed mortality risk occurred in patients with MVPA ≥150 min/week and alcohol consumption 8.4–15.4 drinks/week (HR = 0.348, 95% CI: 0.169–0.667). Comparably lower risk was seen with MVPA <150 min/week plus light alcohol intake (150 min/week of MVPA alongside light to moderate alcohol consumption (<15.4 drinks/week). However, comparable survival benefits were observed with <150 min/week of MVPA when coupled with light alcohol intake. MVPA remains the cornerstone for mortality risk reduction in this population.
- 2 September 2025
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1616561
Open AccessAssociation between joint physical activity and alcohol intake and all-cause mortality in patients with cardiovascular disease: findings from NHANES 2007–2018
Background: Physical activity and alcohol consumption are both highly prevalent in many countries, while the evidence related to joint effect on physical activity and alcohol consumption on patients with cardiovascular disease (CVD) was still deficient. This study was aimed to investigate the association between joint moderate-to-vigorous physical activity (MVPA) and alcohol intake and all-cause mortality in patients with CVD.Methods: A total of 4,047 participants from the National Health and Nutrition Examination Survey (NHANES) with self-reported CVD history, exercise and alcohol consumption amounts were included this study. Participants were stratified into 12 groups by MVPA level (none/insufficient/sufficient) and alcohol intake (abstainer/light/moderate/heavy). Restricted cubic spline and Cox regression models assessed mortality associations.Results: MVPA showed an L-shaped association with mortality, while alcohol exhibited a U-shaped pattern. The lowest observed mortality risk occurred in patients with MVPA ≥150 min/week and alcohol consumption 8.4–15.4 drinks/week (HR = 0.348, 95% CI: 0.169–0.667). Comparably lower risk was seen with MVPA <150 min/week plus light alcohol intake (150 min/week of MVPA alongside light to moderate alcohol consumption (<15.4 drinks/week). However, comparable survival benefits were observed with <150 min/week of MVPA when coupled with light alcohol intake. MVPA remains the cornerstone for mortality risk reduction in this population.
- Open Access
- 13 March 2025
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 53 (3)
Staged intervention in a patient with concomitant giant abdominal aortic aneurysm and hepatic artery
Abdominal aortic aneurysms are the most common types of aneurysms worldwide, whereas aneurysms in the blood vessels of the abdominal organs (splanchnic aneurysms) are rare. Few studies have reported cases of two giant aneurysms occurring simultaneously. Presented here is a case of a 67-year-old man who began to experience periumbilical pain with a diagnosis of a giant abdominal aortic aneurysm and a hepatic artery aneurysm. He was successfully treated using a staged endovascular stent grafting procedure. Postoperatively, the patient’s abdominal pain was resolved, and he was prescribed medication for hypertension control, lipid control, heart rate control, antiplatelet therapy, and smoking cessation, which he took regularly. Follow-up evaluations were performed at 3, 6, and 9 months after surgery, and no late complications were observed. This case report suggests that when two giant aneurysms are diagnosed simultaneously, risk of rupture, surgical interventions, and postoperative complications are significantly increased. The choice of a treatment strategy is complex and has a high degree of individual specificity.
- 13 March 2025
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 53 (3)
Open AccessStaged intervention in a patient with concomitant giant abdominal aortic aneurysm and hepatic artery
Abdominal aortic aneurysms are the most common types of aneurysms worldwide, whereas aneurysms in the blood vessels of the abdominal organs (splanchnic aneurysms) are rare. Few studies have reported cases of two giant aneurysms occurring simultaneously. Presented here is a case of a 67-year-old man who began to experience periumbilical pain with a diagnosis of a giant abdominal aortic aneurysm and a hepatic artery aneurysm. He was successfully treated using a staged endovascular stent grafting procedure. Postoperatively, the patient’s abdominal pain was resolved, and he was prescribed medication for hypertension control, lipid control, heart rate control, antiplatelet therapy, and smoking cessation, which he took regularly. Follow-up evaluations were performed at 3, 6, and 9 months after surgery, and no late complications were observed. This case report suggests that when two giant aneurysms are diagnosed simultaneously, risk of rupture, surgical interventions, and postoperative complications are significantly increased. The choice of a treatment strategy is complex and has a high degree of individual specificity.
- Open Access
- 1 January 2025
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 23 (1) , 57-66
Energy Metabolism Dysregulation in Myocardial Infarction: An Integrative Analysis of Ischemic Cardiomyopathy
Background: Myocardial metabolism is closely related to functional changes after myocardial infarction (MI). Objective: This study aimed to present an integrative examination of human ischemic cardiomyopathy. Methods: We used both GSE121893 single-cell suspension sequencing and GSE19303 transcription microarray data sets from the GEO database, along with a murine MI model for full-spectrum metabolite detection. Through a systematic investigation that involved differential metabolite identification and functional enrichment analysis, we shed light on the pivotal role of energy metabolism dysregulation in the progression of MI. Results: Our findings revealed an association between the core regulatory genes CDKN1A, FOS, ITGB4, and MAP2K1 and the underlying pathophysiology of the disease. These genes are identified as critical elements in the complex landscape of myocardial ischemic disorder, highlighting novel insights into therapeutic targets and the intricate biological mechanisms involved. Conclusion: This analysis provides a framework for future research on the metabolic alterations associated with MI.
- 1 January 2025
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 23 (1) , 57-66
Open AccessEnergy Metabolism Dysregulation in Myocardial Infarction: An Integrative Analysis of Ischemic Cardiomyopathy
Background: Myocardial metabolism is closely related to functional changes after myocardial infarction (MI). Objective: This study aimed to present an integrative examination of human ischemic cardiomyopathy. Methods: We used both GSE121893 single-cell suspension sequencing and GSE19303 transcription microarray data sets from the GEO database, along with a murine MI model for full-spectrum metabolite detection. Through a systematic investigation that involved differential metabolite identification and functional enrichment analysis, we shed light on the pivotal role of energy metabolism dysregulation in the progression of MI. Results: Our findings revealed an association between the core regulatory genes CDKN1A, FOS, ITGB4, and MAP2K1 and the underlying pathophysiology of the disease. These genes are identified as critical elements in the complex landscape of myocardial ischemic disorder, highlighting novel insights into therapeutic targets and the intricate biological mechanisms involved. Conclusion: This analysis provides a framework for future research on the metabolic alterations associated with MI.
- Open Access
- 17 December 2024
- Published by Akademiai Kiado Zrt. in Acta Microbiologica Et Immunologica Hungarica
Application of metagenomic next-generation sequencing in pathogen detection for patients with lower respiratory tract infections caused by multidrug-resistant organisms and analysis of related factors
The incidence of lower respiratory tract infections (LRTIs) caused by multidrug-resistant organisms (MDRO) has been high in recent years. However, traditional etiological detection methods have not been able to meet the needs for clinical diagnosis and prognosis of LRTIs. The rapid development of metagenomic next-generation sequencing (mNGS) provides new insights for diagnosis and treatment of LRTIs. We conducted a retrospective study on 95 patients with lower respiratory tract infections caused by MDRO admitted to our respiratory department from January 2022 to December 2023. These patients underwent mNGS testing and conventional culture testing. Additionally, 150 patients without lower respiratory tract infections caused by MDRO during the same period were included as the non-MDRO group. General information was collected, and Logistic regression analysis was performed to identify risk factors for MDRO infections in patients with lower respiratory tract infections. Our results show that the time to pathogen detection by mNGS was 50.76 ± 1.730 h, that is significantly shorter than 55.53 ± 2.782 h required for conventional culture testing. The pathogen detection rate by mNGS was 89.47% (85/95), higher than the 67.37% (64/95) identified by conventional testing. In terms of pathogen genus distribution, mNGS detected a total of 279 pathogens, while conventional testing detected 121 pathogens. Logistic multivariate regression analysis identified that the use of more than two antibiotics, invasive procedures, invasive mechanical ventilation for ≥7 days, and stay in the respiratory intensive care unit (RICU) for ≥7 days were the main influencing factors for lower respiratory tract infections caused by MDRO (P < 0.05).
- 17 December 2024
- Published by Akademiai Kiado Zrt. in Acta Microbiologica Et Immunologica Hungarica
Open AccessApplication of metagenomic next-generation sequencing in pathogen detection for patients with lower respiratory tract infections caused by multidrug-resistant organisms and analysis of related factors
The incidence of lower respiratory tract infections (LRTIs) caused by multidrug-resistant organisms (MDRO) has been high in recent years. However, traditional etiological detection methods have not been able to meet the needs for clinical diagnosis and prognosis of LRTIs. The rapid development of metagenomic next-generation sequencing (mNGS) provides new insights for diagnosis and treatment of LRTIs. We conducted a retrospective study on 95 patients with lower respiratory tract infections caused by MDRO admitted to our respiratory department from January 2022 to December 2023. These patients underwent mNGS testing and conventional culture testing. Additionally, 150 patients without lower respiratory tract infections caused by MDRO during the same period were included as the non-MDRO group. General information was collected, and Logistic regression analysis was performed to identify risk factors for MDRO infections in patients with lower respiratory tract infections. Our results show that the time to pathogen detection by mNGS was 50.76 ± 1.730 h, that is significantly shorter than 55.53 ± 2.782 h required for conventional culture testing. The pathogen detection rate by mNGS was 89.47% (85/95), higher than the 67.37% (64/95) identified by conventional testing. In terms of pathogen genus distribution, mNGS detected a total of 279 pathogens, while conventional testing detected 121 pathogens. Logistic multivariate regression analysis identified that the use of more than two antibiotics, invasive procedures, invasive mechanical ventilation for ≥7 days, and stay in the respiratory intensive care unit (RICU) for ≥7 days were the main influencing factors for lower respiratory tract infections caused by MDRO (P < 0.05).
- Open Access
- 11 January 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1280547
SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis
Coronary heart disease is a narrowing or obstruction of the vascular cavity caused by atherosclerosis of the coronary arteries, which leads to myocardial ischemia and hypoxia. At present, percutaneous coronary intervention (PCI) is an effective treatment for coronary atherosclerotic heart disease. Restenosis is the main limiting factor of the long-term success of PCI, and it is also a difficult problem in the field of intervention. Sodium-glucose cotransporter 2 (SGLT2) inhibitor is a new oral glucose-lowering agent used in the treatment of diabetes in recent years. Recent studies have shown that SGLT2 inhibitors can effectively improve the prognosis of patients after PCI and reduce the occurrence of restenosis. This review provides an overview of the clinical studies and mechanisms of SGLT2 inhibitors in the prevention of restenosis, providing a new option for improving the clinical prognosis of patients after PCI.
- 11 January 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1280547
Open AccessSGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis
Coronary heart disease is a narrowing or obstruction of the vascular cavity caused by atherosclerosis of the coronary arteries, which leads to myocardial ischemia and hypoxia. At present, percutaneous coronary intervention (PCI) is an effective treatment for coronary atherosclerotic heart disease. Restenosis is the main limiting factor of the long-term success of PCI, and it is also a difficult problem in the field of intervention. Sodium-glucose cotransporter 2 (SGLT2) inhibitor is a new oral glucose-lowering agent used in the treatment of diabetes in recent years. Recent studies have shown that SGLT2 inhibitors can effectively improve the prognosis of patients after PCI and reduce the occurrence of restenosis. This review provides an overview of the clinical studies and mechanisms of SGLT2 inhibitors in the prevention of restenosis, providing a new option for improving the clinical prognosis of patients after PCI.
- Open Access
- 16 September 2023
- Published by Elsevier in International Journal of Cardiology
- Vol. 394, 131363
LKB1 delays atherosclerosis by inhibiting phenotypic transformation of vascular smooth muscle cells
- 16 September 2023
- Published by Elsevier in International Journal of Cardiology
- Vol. 394, 131363
Open AccessLKB1 delays atherosclerosis by inhibiting phenotypic transformation of vascular smooth muscle cells
- Open Access
- 10 March 2023
- Published by Springer Nature in Research Square
LKB1 delays atherosclerosis by inhibiting phenotypic transformation of vascular smooth muscle cells
Background and objective: Although liver kinase B1 (LKB1) is a well-known tumor suppressor gene, and its encoded protein has important biological functions, it is not clear whether LKB1 can inhibit atherosclerosis by regulating vascular smooth muscle cells (VSMCs). The purpose of this study is to explore the relationship among LKB1, VSMCs and atherosclerosis. Methods and results: ApoE-/- mice with VSMCs-specific overexpression of LKB1 were constructed by adeno-associated virus transfection technique, and then fed with high-fat diet for eight weeks. The effect of LKB1 overexpression on atherosclerosis in mice was investigated by oil red O staining, HE staining, immunofluorescence and Western Blot. The results showed that the expression of LKB1 mRNA and protein in arterial tissue of mice increased significantly after overexpression of LKB1. The degree of atherosclerosis, smooth muscle fiber proliferation and lipid accumulation were significantly alleviated in the overexpression group. The results of Western Blot showed that the expression of α-SMA was increased, while the expression of OPN and CD68 was significantly decreased in the overexpression group (PConclusion: Our results suggested that LKB1 can delay the progression of atherosclerosis by inhibiting the phenotypic transition of VSMCs.
- 10 March 2023
- Published by Springer Nature in Research Square
Open AccessLKB1 delays atherosclerosis by inhibiting phenotypic transformation of vascular smooth muscle cells
Background and objective: Although liver kinase B1 (LKB1) is a well-known tumor suppressor gene, and its encoded protein has important biological functions, it is not clear whether LKB1 can inhibit atherosclerosis by regulating vascular smooth muscle cells (VSMCs). The purpose of this study is to explore the relationship among LKB1, VSMCs and atherosclerosis. Methods and results: ApoE-/- mice with VSMCs-specific overexpression of LKB1 were constructed by adeno-associated virus transfection technique, and then fed with high-fat diet for eight weeks. The effect of LKB1 overexpression on atherosclerosis in mice was investigated by oil red O staining, HE staining, immunofluorescence and Western Blot. The results showed that the expression of LKB1 mRNA and protein in arterial tissue of mice increased significantly after overexpression of LKB1. The degree of atherosclerosis, smooth muscle fiber proliferation and lipid accumulation were significantly alleviated in the overexpression group. The results of Western Blot showed that the expression of α-SMA was increased, while the expression of OPN and CD68 was significantly decreased in the overexpression group (PConclusion: Our results suggested that LKB1 can delay the progression of atherosclerosis by inhibiting the phenotypic transition of VSMCs.
- Open Access
- 28 March 2022
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 50 (3)
Implantation of a dual-chamber pacemaker in a patient with dextrocardia and sick sinus syndrome: a case report
Dextrocardia is a congenital abnormal position of the heart in which the main part of the heart is in the right chest, and the long axis of the heart points to the lower right. Cases of a combination of dextrocardia and sick sinus syndrome are rare. A 65-year-old female patient was admitted to hospital with palpitations and dizziness for 1 week. Mirror-image dextrocardia and sick sinus syndrome were diagnosed by an electrocardiogram, echocardiography, Holter monitoring, and X-rays. Finally, we successfully implanted a dual-chamber pacemaker into the patient. The patient had an uneventful recovery and was discharged when her symptoms had greatly improved 1 week later. When dextrocardia is present, using active fixation leads in the atrial and ventricular leads is easier for finding the pacing position with optimal sensing and pacing thresholds, and they reduce the incidence of falling off.
- 28 March 2022
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 50 (3)
Open AccessImplantation of a dual-chamber pacemaker in a patient with dextrocardia and sick sinus syndrome: a case report
Dextrocardia is a congenital abnormal position of the heart in which the main part of the heart is in the right chest, and the long axis of the heart points to the lower right. Cases of a combination of dextrocardia and sick sinus syndrome are rare. A 65-year-old female patient was admitted to hospital with palpitations and dizziness for 1 week. Mirror-image dextrocardia and sick sinus syndrome were diagnosed by an electrocardiogram, echocardiography, Holter monitoring, and X-rays. Finally, we successfully implanted a dual-chamber pacemaker into the patient. The patient had an uneventful recovery and was discharged when her symptoms had greatly improved 1 week later. When dextrocardia is present, using active fixation leads in the atrial and ventricular leads is easier for finding the pacing position with optimal sensing and pacing thresholds, and they reduce the incidence of falling off.
- Open Access
- 28 February 2022
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 50 (2)
Coronary artery–left ventricular multiple microfistulas, a rare disease that is easily missed: case report and literature review
Coronary artery–left ventricular multiple microfistulas (CALVMMFs) are a very rare type of coronary artery fistula. Because of their special anatomical structure and hemodynamics, CALVMMFs often result in no obvious symptoms and signs. Most patients are diagnosed by coronary angiography; however, as a routine noninvasive screening method, Doppler echocardiography is a potential first-choice diagnostic technique for patients with CALVMMFs. Although satisfactory results of CALVMMF closure are difficult to achieve, the clinical symptoms of these patients are not obvious, and drug therapy has a clear therapeutic effect on most patients. We herein introduce seven cases of CALVMMFs confirmed by our hospital and briefly review the related literature.
- 28 February 2022
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 50 (2)
Open AccessCoronary artery–left ventricular multiple microfistulas, a rare disease that is easily missed: case report and literature review
Coronary artery–left ventricular multiple microfistulas (CALVMMFs) are a very rare type of coronary artery fistula. Because of their special anatomical structure and hemodynamics, CALVMMFs often result in no obvious symptoms and signs. Most patients are diagnosed by coronary angiography; however, as a routine noninvasive screening method, Doppler echocardiography is a potential first-choice diagnostic technique for patients with CALVMMFs. Although satisfactory results of CALVMMF closure are difficult to achieve, the clinical symptoms of these patients are not obvious, and drug therapy has a clear therapeutic effect on most patients. We herein introduce seven cases of CALVMMFs confirmed by our hospital and briefly review the related literature.
- Open Access
- 13 December 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Translational Engineering in Health and Medicine
- Vol. 10, 1-7
Evaluation of a Novel Left Ventricular Assist Device for Resuscitation in an Animal Model of Ventricular Fibrillation Cardiac Arrest
We evaluated an independently developed novel percutaneous implantable left ventricular assist device for resuscitation in a pig model of ventricular fibrillation cardiac arrest. The model was established in 10 domestic pigs by blocking the anterior descending coronary artery with a balloon after anesthesia. With ventilator-assisted ventilation, the independently developed percutaneous implantable left ventricular assist device was inserted via the femoral artery to assist circulation. According to whether effective circulatory support was achieved, the pigs were randomly divided into an experimental group and a control group. The experimental group was subjected to insertion of the assist device and received continuous circulatory support. The control group underwent insertion of the assist device; however, it did not start it within 15 minutes. For all animals, if successful rescue was achieved (sinus rhythm restoration within 15 minutes and maintenance for over 5 minutes), circulatory support was stopped, and the arterial blockage was removed. If sinus rhythm was not restored within 15 minutes, electric defibrillation, adrenaline injection, and removal of the arterial blockage were performed, and circulatory support was provided until sinus rhythm recovered. A determination of failed rescue was made when sinus rhythm was not restored after 1 hour. All successfully rescued animals were fed for 1 week. There were no significant differences in baseline data between the groups. All animals underwent successful novel left ventricular assist device implantation through the femoral artery. The rescue rate was significantly higher in the experimental group than in the control group (80% vs. 0%, P = 0.01). All successfully rescued animals survived after 1 week of feeding, and no eating or movement abnormalities were observed. We conclude that this independently developed percutaneous implantable left ventricular assist device can be conveniently and rapidly implanted through the femoral artery and can maintain basic circulatory perfusion during resuscitation in an animal model of cardiac arrest.
- 13 December 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Translational Engineering in Health and Medicine
- Vol. 10, 1-7
Open AccessEvaluation of a Novel Left Ventricular Assist Device for Resuscitation in an Animal Model of Ventricular Fibrillation Cardiac Arrest
We evaluated an independently developed novel percutaneous implantable left ventricular assist device for resuscitation in a pig model of ventricular fibrillation cardiac arrest. The model was established in 10 domestic pigs by blocking the anterior descending coronary artery with a balloon after anesthesia. With ventilator-assisted ventilation, the independently developed percutaneous implantable left ventricular assist device was inserted via the femoral artery to assist circulation. According to whether effective circulatory support was achieved, the pigs were randomly divided into an experimental group and a control group. The experimental group was subjected to insertion of the assist device and received continuous circulatory support. The control group underwent insertion of the assist device; however, it did not start it within 15 minutes. For all animals, if successful rescue was achieved (sinus rhythm restoration within 15 minutes and maintenance for over 5 minutes), circulatory support was stopped, and the arterial blockage was removed. If sinus rhythm was not restored within 15 minutes, electric defibrillation, adrenaline injection, and removal of the arterial blockage were performed, and circulatory support was provided until sinus rhythm recovered. A determination of failed rescue was made when sinus rhythm was not restored after 1 hour. All successfully rescued animals were fed for 1 week. There were no significant differences in baseline data between the groups. All animals underwent successful novel left ventricular assist device implantation through the femoral artery. The rescue rate was significantly higher in the experimental group than in the control group (80% vs. 0%, P = 0.01). All successfully rescued animals survived after 1 week of feeding, and no eating or movement abnormalities were observed. We conclude that this independently developed percutaneous implantable left ventricular assist device can be conveniently and rapidly implanted through the femoral artery and can maintain basic circulatory perfusion during resuscitation in an animal model of cardiac arrest.